Zeitview Acquires Heliolytics, Becoming the Market Leader in Solar Aerial Inspections
6.9.2023 13:00:00 EEST | Business Wire | Press release
Zeitview today takes the lead in advanced aerial inspections for energy and infrastructure by acquiring Heliolytics, which specializes in photovoltaic (PV) system performance via aerial inspection and integrated analytics. The acquisition of this former division of NovaSource Power Services enables the combining of Heliolytics' data insights with Zeitview’s expertise in aerial inspection technologies. The majority of Heliolytics staff will join Zeitview, and the team’s presence in Toronto, Canada, will continue. The amount of the deal was not disclosed.
"Heliolytics are pioneers in the solar industry and have earned a commendable reputation for their unwavering commitment to quality, precision, and exceptional customer service—values we hold in the highest esteem,” said Dan Burton, founder and Chief Executive Officer at Zeitview. “Their expertise and dedication are valuable as we continue developing groundbreaking solutions that redefine inspection standards within the renewable energy sector. We are excited for this next chapter in our journey, where our united teams create a complete market-winning solution."
For renewable energy customers, this collaboration reinforces Zeitview's multi-asset approach to solar, wind, and utilities. For property owners, it offers critical insights into the performance of their rooftop solar facilities. For all customers, Heliolytics' international operations in Europe, Latin America, and the Asian Pacific are also being combined with Zeitview's global footprint in those same regions.
“Joining forces with Zeitview is a tremendous opportunity to further the renewable energy industry,” said Jocelyne Moyer, Head of Heliolytics. Post-acquisition, Moyer takes the title of Senior Director of Strategy and Operations at Zeitview. “We have a shared commitment with Zeitview to deep client partnerships, science-driven innovation, and unparalleled responsiveness to our global clients. I am excited to join the leadership team and look forward to collaborations that will strengthen Zeitview’s role in the operations and maintenance of renewable energy assets.”
Heliolytics' inspection tools and integrated analytics are now supported by Zeitview's AI/ML data processing engine. With this addition, Zeitview doubles the reach and breadth of its airplane operations and adds topography, EPC, and drone solutions to Heliolytics, all of which can translate into faster, more comprehensive customer results.
With the sale of Heliolytics to Zeitview, NovaSource Power Services continues to offer best-in-class aerial inspection software and services to their customers via Zeitview.
“We are thrilled to continue our longstanding partnership with the Heliolytics team under the Zeitview name,” said Timo Moeller, Chief Growth Officer, NovaSource Power Services. “Zeitview’s impressive inspection and software tools will enhance the insights we currently use to support operations and maintenance requests. It is clear that the Zeitview team deeply understands our data needs and is committed to providing continued unrivaled expertise as aerial inspection providers to support our growth.”
A complete integration of Heliolytics operations, data capture, and software into Zeitview’s market-leading global solar solution is expected to be finished by the end of 2024.
To learn more about how Zeitview supports global energy and infrastructure through advanced inspections and actionable data, visit www.zeitview.com.
ABOUT ZEITVIEW
As a single partner for aerial inspections across a broad spectrum of industries, including solar, wind, real estate, telecom, and utility assets, Zeitview is trusted by the largest enterprises worldwide to deliver fast, accurate insights that optimize asset performance and reduce operating and maintenance costs. Combining state-of-the-art aerial inspection software with the ability to capture in-depth visual data via airplanes and drones, Zeitview harnesses the power of artificial intelligence and machine learning. Such aerial intelligence delivers customers actionable insights in near real-time and empowers organizations to make better-informed decisions about their most critical assets at scale.
Learn more about Zeitview's cutting-edge solutions at www.zeitview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906378784/en/
Contact information
Technica Communications for Zeitview
Cait Caviness
zeitview@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
